Lower back pain treatment often starts with simple relief

Regular movement usually helps more than long bed rest

Keep doing the tasks you can manage without forcing sharp soreness. Short walks and easy exercises often help a stiff back. A physical therapist can help you build strength without doing too much too soon, though the work takes time.

Warmth can calm a new ache for a while. Medicine may help you move or sleep, though side effects still matter. Ask your doctor how it works with the pills you already take, and don't borrow another person's dose.

When one activity leaves you sore for days, change the amount before giving it up. A shorter walk or a lighter load may be enough. Add time only after your back settles by the next day because steady practice is useful.

PRP for back pain is a blood-based shot with limits

Platelet-rich plasma, shortened to PRP, is made by spinning a sample of your blood until one part is concentrated. QC Kinetix offers it among its non-surgical regenerative treatments, meaning blood-based care given by trained health workers called medical providers. The hoped-for result is less soreness, but back research is still limited. It can't promise relief or rebuild a worn disc.

Before any shot, the exam needs to explain why the clinic thinks one sore area is causing your trouble. The health worker may check movement, strength, feeling, and where soreness travels. Ask what that exam found, what result would be reasonable, and why most health plans won't pay for this care.

Surgery may help when an exam and scan show a problem that an operation can address. It isn't the first answer for every worn disc or lasting ache. A doctor can explain the problem surgery would correct, along with the risks of waiting. That answer needs to be specific.

The right choice should match your daily goal

A treatment earns its cost when it helps with a task that matters to you. That may mean standing through supper or walking around the block. A small change may matter more than a better-looking scan because daily life is the test.

Ask how soon easier movement or better sleep might appear. The clinic may honestly say it can't predict whether relief will come. It may also set a stopping time if nothing changes, and that's a useful answer.

Sources

1. The 2017 American College of Physicians guideline makes a STRONG recommendation that acute and subacute low back pain be treated first with non-drug care - superficial heat, massage, acupuncture or spinal manipulation - because most patients improve over time regardless of treatment, and a STRONG recommendation that chronic low back pain be treated first with exercise, multidisciplinary rehabilitation, acupuncture, mindfulness-based stress reduction, tai chi, yoga, motor control exercise, progressive relaxation, EMG biofeedback, low-level laser therapy, operant therapy, cognitive behavioural therapy or spinal manipulation. Drugs are second, and opioids are a weak recommendation of last resort.

   Qaseem A, Wilt TJ, McLean RM, et al. — Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians.. Annals of Internal Medicine, 2017. DOI: 10.7326/M16-2367.

2. A 2025 Cochrane overview of 31 Cochrane reviews covering 644 trials and 97,183 adults found that exercise therapies probably reduce chronic low back pain by 15.2 points on a 0-100 scale versus no treatment or usual care and improve function by 6.8 points, that multidisciplinary therapies probably produce a medium pain reduction, that acupuncture probably improves function only slightly versus sham, that traction is probably no different from sham traction, and that spinal manipulation probably makes no difference to function versus placebo in acute low back pain.

   Rizzo RR, Cashin AG, Wand BM, et al. — Non-pharmacological and non-surgical treatments for low back pain in adults: an overview of Cochrane reviews.. Cochrane Database of Systematic Reviews, 2025. DOI: 10.1002/14651858.CD014691.pub2.

3. The Cochrane review of exercise therapy for chronic low back pain pooled 249 trials and found moderate-certainty evidence of a clinically important 15.2-point pain reduction (0-100 scale) versus no treatment, usual care or placebo. The effect on functional limitations was 6.8 points, which did NOT meet the review's own threshold for a minimal clinically important difference, and adverse effects were mostly minor muscle soreness.

   Hayden JA, Ellis J, Ogilvie R, Malmivaara A, van Tulder MW — Exercise therapy for chronic low back pain.. Cochrane Database of Systematic Reviews, 2021. DOI: 10.1002/14651858.CD009790.pub2.

4. The RESTORE trial randomised 492 people with chronic disabling low back pain across 20 primary-care physiotherapy clinics to usual care, cognitive functional therapy, or cognitive functional therapy with movement-sensor biofeedback. Both therapy arms produced a 4.6-point improvement on the 24-point Roland Morris Disability Questionnaire versus usual care at 13 weeks, with similar effect sizes still present at 52 weeks and substantially lower societal costs. Adding the sensor added nothing.

   Kent P, Haines T, O'Sullivan P, et al. — Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): a randomised, controlled, three-arm, parallel group, phase 3, clinical trial.. The Lancet, 2023. DOI: 10.1016/S0140-6736(23)00441-5.

5. A meta-analysis of 35 placebo-controlled randomised trials found NSAIDs reduce spinal pain and disability, but by an amount below the threshold for clinical importance: six people must be treated with an NSAID rather than placebo for one additional person to achieve clinically important pain reduction, and NSAIDs raised the risk of gastrointestinal reactions 2.5-fold. The authors conclude that no simple analgesic provides clinically important effects for spinal pain over placebo.

   Machado GC, Maher CG, Ferreira PH, et al. — Non-steroidal anti-inflammatory drugs for spinal pain: a systematic review and meta-analysis.. Annals of the Rheumatic Diseases, 2017. DOI: 10.1136/annrheumdis-2016-210597.

6. The only double-blind randomised trial of intradiscal PRP for discogenic low back pain enrolled 47 participants (29 PRP, 18 control) and reported statistically significant improvements in pain, function and satisfaction over EIGHT WEEKS compared with a contrast-agent control. It is a small, single-centre trial, the control group was offered crossover to PRP at 8 weeks, and no disc infection, neurological injury or progressive herniation was reported. The authors themselves call the results promising and say further studies are needed to define who responds.

   Tuakli-Wosornu YA, Terry A, Boachie-Adjei K, et al. — Lumbar Intradiskal Platelet-Rich Plasma (PRP) Injections: A Prospective, Double-Blind, Randomized Controlled Study.. PM&R, 2016. DOI: 10.1016/j.pmrj.2015.08.010.

7. A follow-up of a SUBSET of patients from that intradiscal PRP trial, contacted once at 5-9 years post-injection, reported statistically and clinically significant improvements in pain and function versus their own baseline. Six patients had gone on to surgery during the interval. This is an uncontrolled long-term look at a subset, not a controlled comparison, and cannot separate treatment effect from natural history.

   Cheng J, Santiago KA, Nguyen JT, Solomon JL, Lutz GE — Treatment of symptomatic degenerative intervertebral discs with autologous platelet-rich plasma: follow-up at 5-9 years.. Regenerative Medicine, 2019. DOI: 10.2217/rme-2019-0040.

8. A 2024 systematic review and SINGLE-ARM meta-analysis of intradiscal regenerative therapies found only 8 randomised trials and 8 observational studies in the entire literature, and graded the evidence 'fair (Level III) with limited certainty', naming the paucity of high-quality studies as its central limitation. A single-arm meta-analysis pools before-and-after change without a comparison group, so it cannot separate the injection from natural history or placebo.

   Manchikanti L, Knezevic E, Knezevic NN, et al. — Effectiveness of Intradiscal Regenerative Medicine Therapies for Long-Term Relief of Chronic Low Back Pain: A Systematic Review and Meta-Analysis.. Pain Physician, 2024.

9. The 2025 ASIPP regenerative-therapy guideline for chronic low back pain - written by the specialty society that performs these procedures - grades the evidence as Level III (fair) for intradiscal PRP, Level III (fair) for intradiscal bone marrow concentrate, Level III (fair) for epidural PRP, Level IV (limited) for facet joint PRP and MSC injections, Level IV (limited) for sacroiliac joint PRP, and very low for functional-spine-unit injections. All 19 recommendations are consensus-based rather than evidence-driven, the panel names the scarcity of high-quality studies as the primary limitation, and it states that most of these therapies are not covered by commercial insurance.

   Manchikanti L, Navani R, Navani A, et al. — Comprehensive Evidence-Based Guidelines for Regenerative Therapies in the Management of Chronic Low Back Pain: 2025 Update from the American Society Of Interventional Pain Physicians (ASIPP).. Pain Physician, 2025.

10. The 2023 Cochrane review of spinal cord stimulation for low back pain included 13 studies and 699 participants and found NO study evaluated pain at 12 months or beyond. At six months, moderate-certainty evidence from the single available placebo-controlled trial showed SCS probably does not improve back or leg pain, function or quality of life versus placebo. In one study 13 of 42 people (31%) required revision surgery within 24 months. The authors state the data 'do not support the use of SCS to manage low back pain outside a clinical trial.'

    Traeger AC, Gilbert SE, Harris IA, Maher CG — Spinal cord stimulation for low back pain.. Cochrane Database of Systematic Reviews, 2023. DOI: 10.1002/14651858.CD014789.pub2.

11. The FDA states verbatim that stem cell products, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products have NOT been 'approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' No stem cell product is approved in the United States for any orthopedic use: the only ones with FDA approval at all are blood-forming cells derived from umbilical cord blood, approved solely for disorders of blood production, and there are currently no FDA-approved exosome products.

    U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes.. FDA.gov, 2025.